Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sets New 1-Year High at $11.10

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) reached a new 52-week high during trading on Tuesday . The company traded as high as $11.10 and last traded at $10.77, with a volume of 41881 shares. The stock had previously closed at $7.19.

Shionogi & Co., Ltd. Stock Up 49.7 %

The company has a current ratio of 5.86, a quick ratio of 5.37 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $11.06 and its two-hundred day moving average is $11.14. The company has a market capitalization of $12.78 billion, a PE ratio of 12.64, a P/E/G ratio of 2.37 and a beta of 0.23.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last announced its earnings results on Monday, July 29th. The company reported $0.17 earnings per share for the quarter. The business had revenue of $625.99 million for the quarter. Shionogi & Co., Ltd. had a return on equity of 11.95% and a net margin of 35.53%. As a group, analysts predict that Shionogi & Co., Ltd. will post 0.96 EPS for the current year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.